What's happening
This bill directs the New York Department of Health to study the effects and diagnosis trends of ADHD medications in school-age children.
Why it matters
Focuses on potential side effects and safety concerns. By specifically directing the study to examine harmful side effects of ADHD-related medications, the bill addresses worries about the physical and mental health risks for children using these drugs.
Evaluates diagnostic practices and medication appropriateness. The research will scrutinize how ADHD and related disorders are diagnosed in school-age children, including whether current tools and methods are suitable, and if prescribed medications are the most appropriate choices for young patients.
Highlights demographic disparities. The study is tasked with investigating whether there are differences in diagnosis and treatment based on demographic factors (such as race, gender, or socioeconomic status), aiming to identify and address potential inequities in ADHD diagnosis and care.
Potential to inform future healthcare and education policy. By requiring a formal report to state leadership, the bill could influence future regulations, school procedures, and healthcare guidelines surrounding ADHD diagnosis and medication in children.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Study ADHD Drug Effects
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Study ADHD Drug Use
In Senate Committee · Health · Sponsor Kevin S. Parker
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
3439
2019-2020 Regular Sessions
IN ASSEMBLY
January 29, 2019
Introduced by M. of A. WALKER -- read once and referred to the Committee on Health
AN ACT authorizing and directing the department of health to do research and study as to the effects of psychostimulants, selective seratonin reuptake inhibitors, antidepressants and other drugs which are prescribed for attention deficit disorders, ADD and ADHD, for school age children
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. 1. The commissioner of health, in conjunction with the commissioner of mental health, the commissioner of developmental disabilities, and the commissioner of education is authorized and directed to conduct a study and do research as to the effect of psychostimulants, selective serotonin reuptake inhibitors, antidepressants and other drugs prescribed for attention deficit disorder, attention deficit hyperactivity disorder, and the increasing rate of diagnosis of these conditions, in school age children.
2. The study shall be conducted in accordance with rules, regulations and standards determined by the commissioner of health, and the study shall concentrate on harmful side effects of such drugs, the appropriateness and effectiveness of tools and methods used to assess and diagnose the condition, the appropriateness of different medications, and any demographic disparities in diagnosis.
3. The commissioner of health shall report his or her findings to the governor, the speaker of the assembly and the temporary president of the senate on or before two years from the date this act shall take effect.
§ 2. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05949-01-9
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.